|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2006-12-14
|
|
pubmed:abstractText |
Phase III trials evaluating the efficacy of gefitinib (IRESSA) in non-small cell lung cancer (NSCLC) lend support to the need for improved patient selection in terms of gefitinib use. Mutation of the epidermal growth factor receptor (EGFR) gene is reported to be associated with clinical responsiveness to gefitinib. However, gefitinib-sensitive and prolonged stable-disease-defined tumors without EGFR gene mutation have also been reported.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/17150102-10085130,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17150102-10470842,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17150102-11156248,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17150102-11289158,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17150102-11980995,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17150102-12384534,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17150102-15118073,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17150102-15118125,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17150102-15292385,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17150102-15492792,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17150102-15665299,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17150102-15710947,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17150102-15777982,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17150102-15870435,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17150102-15870831,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17150102-15998906,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17150102-16424029,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17150102-16638863,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17150102-6606682,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17150102-7612182,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17150102-7683573,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17150102-8938142,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17150102-9484787
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Ligands,
http://linkedlifedata.com/resource/pubmed/chemical/Mitogen-Activated Protein Kinase 1,
http://linkedlifedata.com/resource/pubmed/chemical/Mitogen-Activated Protein Kinase 3,
http://linkedlifedata.com/resource/pubmed/chemical/PTEN Phosphohydrolase,
http://linkedlifedata.com/resource/pubmed/chemical/PTEN protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-akt,
http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Epidermal Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-3,
http://linkedlifedata.com/resource/pubmed/chemical/gefitinib,
http://linkedlifedata.com/resource/pubmed/chemical/p38 Mitogen-Activated Protein...
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1471-2407
|
|
pubmed:author |
pubmed-author:ChenMingweiM,
pubmed-author:GemmaAkihikoA,
pubmed-author:KataokaKiyokoK,
pubmed-author:KokuboYutakaY,
pubmed-author:KosaihiraSeijiS,
pubmed-author:KudohShojiS,
pubmed-author:MatsudaKunikoK,
pubmed-author:MinegishiYujiY,
pubmed-author:NoroRintaroR,
pubmed-author:OkanoTetsuyaT,
pubmed-author:SeikeMasahiroM,
pubmed-author:YoshimuraAkinobuA
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
6
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
277
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:17150102-Antineoplastic Agents,
pubmed-meshheading:17150102-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:17150102-Cell Line, Tumor,
pubmed-meshheading:17150102-Cell Proliferation,
pubmed-meshheading:17150102-DNA Mutational Analysis,
pubmed-meshheading:17150102-Drug Resistance, Neoplasm,
pubmed-meshheading:17150102-Enzyme Activation,
pubmed-meshheading:17150102-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:17150102-Genes, ras,
pubmed-meshheading:17150102-Humans,
pubmed-meshheading:17150102-In Situ Hybridization, Fluorescence,
pubmed-meshheading:17150102-Ligands,
pubmed-meshheading:17150102-Lung Neoplasms,
pubmed-meshheading:17150102-Mitogen-Activated Protein Kinase 1,
pubmed-meshheading:17150102-Mitogen-Activated Protein Kinase 3,
pubmed-meshheading:17150102-PTEN Phosphohydrolase,
pubmed-meshheading:17150102-Phosphorylation,
pubmed-meshheading:17150102-Proto-Oncogene Proteins c-akt,
pubmed-meshheading:17150102-Quinazolines,
pubmed-meshheading:17150102-Receptor, Epidermal Growth Factor,
pubmed-meshheading:17150102-Receptor, erbB-2,
pubmed-meshheading:17150102-Receptor, erbB-3,
pubmed-meshheading:17150102-p38 Mitogen-Activated Protein Kinases
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
|
|
pubmed:affiliation |
Department of Pulmonary Medicine/Infection and Oncology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8602, Japan. r-noro@nms.ac.jp <r-noro@nms.ac.jp>
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
